UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1157-1163

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Journal of clinical oncology, 2011-02, Vol.29 (4), p.398-405

2011

Link zum Volltext

Verfügbarkeit prüfen

An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Blood, 2017-02, Vol.129 (5), p.609-618

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical cancer research, 2017-03, Vol.23 (5), p.1167-1176

2017

Link zum Volltext

Verfügbarkeit prüfen

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

NPJ systems biology and applications, 2020-08, Vol.6 (1), p.28-28, Article 28

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Link zum Volltext

Verfügbarkeit prüfen

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Current drug metabolism, 2012-09, Vol.13 (7), p.901

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer

Journal of clinical pharmacology, 2012-05, Vol.52 (5), p.691-703

2012

Link zum Volltext

Verfügbarkeit prüfen

Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion

Blood, 2008-10, Vol.112 (7), p.2836-2846

2008

Link zum Volltext

Verfügbarkeit prüfen

CCL25 increases thymopoiesis after androgen withdrawal

Blood, 2008-10, Vol.112 (8), p.3255-3263

2008

Link zum Volltext

Verfügbarkeit prüfen

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

Current drug metabolism, 2012-09, Vol.13 (7), p.911

2012

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

Science translational medicine, 2015-05, Vol.7 (287), p.287ra70

2015

Link zum Volltext

Verfügbarkeit prüfen

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

The Lancet. Haematology, 2019-05, Vol.6 (5), p.e254-e265

2019

Link zum Volltext

Verfügbarkeit prüfen

Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution

Blood, 2004-11, Vol.104 (9), p.2794-2800

2004

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia

Future oncology (London, England), 2013-03, Vol.9 (3), p.355-368

2013

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies

The AAPS journal, 2017-05, Vol.19 (3), p.669-681

2017

Link zum Volltext

Verfügbarkeit prüfen

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma

Molecular cancer therapeutics, 2013-07, Vol.12 (7), p.1255-1265

2013

Link zum Volltext

Verfügbarkeit prüfen

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Cancer chemotherapy and pharmacology, 2012-10, Vol.70 (4), p.591-601

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.11-24

2013

Link zum Volltext

Verfügbarkeit prüfen

Murine Models of Chronic Graft-versus-Host Disease: Insights and Unresolved Issues

Biology of blood and marrow transplantation, 2008-04, Vol.14 (4), p.365-378

2008

Link zum Volltext

Verfügbarkeit prüfen

Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function

Blood, 2004-08, Vol.104 (4), p.1110-1119

2004

Link zum Volltext

Verfügbarkeit prüfen

KGF boosts thymic archiTECture

Blood, 2007-05, Vol.109 (9), p.3613-3614

2007

Link zum Volltext

Verfügbarkeit prüfen

Dysregulation of IL-15-mediated T-cell homeostasis in TGF-β dominant-negative receptor transgenic mice

Blood, 2006-10, Vol.108 (8), p.2789-2795

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(56)
Tagungsberichte
(1)

Sprache

Englisch
(57)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(18)
Animals
(12)
Female
(12)
Biological And Medical Sciences
(10)
Hematology
(10)
Mice
(10)
Cell Biology
(8)
Maytansine - Analogs & Derivatives
(8)
Oncology
(8)
Adult
(7)
Immunology
(7)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Trastuzumab
(7)
Aged
(6)
Antibodies, Monoclonal, Humanized - Pharmacokinetics
(6)
Biochemistry
(6)
Breast Neoplasms - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer

Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion

CCL25 increases thymopoiesis after androgen withdrawal

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Murine Models of Chronic Graft-versus-Host Disease: Insights and Unresolved Issues

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function

KGF boosts thymic archiTECture

Dysregulation of IL-15-mediated T-cell homeostasis in TGF-β dominant-negative receptor transgenic mice

Suchergebnisse filtern